Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection

Abstract

Introduction HIV infection has become a chronic, well-treatable disease and the focus of caretakers has shifted to diagnosis and treatment of comorbidities. Hypogonadism in elderly men with HIV might be of particular relevance, however, little is known about its epidemiology in contrast to non-infected peers and men with other chronic medical conditions, such as type 2 diabetes. This study aimed at comparing the prevalence of testosterone deficiency and functional hypogonadism in men ≥ 50 years in these three groups.

Patients and Methods Multi-center, cross-sectional substudy of the German-wide 50/2010 study, including men aged 50 years or older with HIV-infection, type 2 diabetes, and controls.

Results Altogether, 322 men were included (mean age: 62 years (SD±7.9)). The prevalence of testosterone deficiency in men living with HIV, type 2 diabetes, and controls was 34.5, 44.9, and 35.0%, respectively; the prevalence of functional hypogonadism was 7.7, 14.3 and 3.5%, respectively. Single-factor ANOVA demonstrated significant differences between the groups for total testosterone (p<0.001), SHBG (p<0.001), as well as for free testosterone concentrations (p=0.006). Comorbidities were, however, most important single factor in multi-factor analysis.

Discussion Despite a comparable prevalence of testosterone deficiency, functional hypogonadism was more frequent in men living with HIV when compared to non-infected controls. This was the result of a higher burden of symptoms that might, however, also be secondary to other conditions. Number of comorbidities was a more important factor than belonging to one of the groups.

Key words

type 2 diabetes - SHBG - free testosterone - aging males' symptoms

Publication History

Received: 11 May 2020
Received: 10 June 2020

Accepted: 30 June 2020

Article published online:
21 January 2021

• References

• 1 Corona G, Goulis DG, Huhtaniemi I. et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology 2020; 8: 970-987
• 2 Bhasin S, Brito JP, Cunningham GR. et al. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. The. Journal of Clinical Endocrinology and Metabolism 2018; 103: 1715-1744 DOI: 10.1210/jc.2018-00229.
• 3 Beattie MC, Adekola L, Papadopoulos V. et al. Leydig cell aging and hypogonadism. Experimental Gerontology 2015; 68: 87-91 DOI: 10.1016/j.exger.2015.02.014.
• 4 Erenpreiss J, Fodina V, Pozarska R. et al. Prevalence of testosterone deficiency among aging men with and without morbidities. The aging male : The Official Journal of the International Society for the Study of the Aging Male 2019; 1-5 DOI: 10.1080/13685538.2019.1621832.
• 5 Wolf E, Hoffmann C, Schewe K. et al. Symptom and comorbidity burden in chronic disease: comparison of HIV infection and diabetes mellitus in aging patients. Journal of AIDS and Clinical Research 2015; 6: 1-7 DOI: 10.4172/2155-6113.1000527.
• 6 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. The Journal of Clinical Endocrinology and Metabolism 1999; 84: 3666-3672 DOI: 10.1210/jcem.84.10.6079.
• 7 Heinemann LAJ, Zimmermann T, Vermeulen A. et al. A new ‘aging males’ symptoms' rating scale. The Aging Male 1999; 2: 105-114 DOI: 10.3109/13685539909003173.
• 8 Yoshida NM, Kumano H, Kuboki T. Does the Aging Males’ Symptoms scale assess major depressive disorder?: A pilot study. Maturitas 2006; 53: 171-175 DOI: 10.1016/j.maturitas.2005.04.001.
• 9 Lee CP, Jiang JR, Chen Y. et al. The "Aging Males' Symptoms" (AMS) Scale assesses depression and anxiety. The aging male : The Official Journal of the International Society for the Study of the Aging Male 2013; 16: 97-101 DOI: 10.3109/13685538.2013.807428.